Advantages in Prognosis of Adult Patients with Ewing Sarcoma:
11-years Experiences and Current Treatment Management

J 2018

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management

ADÁMKOVÁ KRÁKOROVÁ, Dagmar, Katerina KUBACKOVA, Ladislav DUŠEK, Tomáš TOMÁŠ, Pavel JANÍČEK et. al.

Základní údaje

Originální název

Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management

Autoři

ADÁMKOVÁ KRÁKOROVÁ, Dagmar (203 Česká republika), Katerina KUBACKOVA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Tomáš TOMÁŠ (203 Česká republika), Pavel JANÍČEK (203 Česká republika), Štěpán TUČEK (203 Česká republika), Jana PRAUSOVA (203 Česká republika), Igor KISS (203 Česká republika) a Iva ZAMBO (203 Česká republika, garant)

Vydání

PATHOLOGY & ONCOLOGY RESEARCH, DORDRECHT, SPRINGER, 2018, 1219-4956

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30109 Pathology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.433

Kód RIV

RIV/00216224:14110/18:00103942

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s12253-017-0291-6

UT WoS

000433372000023

Klíčová slova anglicky

Ewing sarcoma; Adults; Multimodal treatment; Risk factors; Prognosis

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 2. 2019 20:07, Soňa Böhmová

Anotace

V originále

Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clinical outcome in a cohort of adult patients treated according to pediatric protocols in the Czech Republic. The records of 58 adult ES patients diagnosed between 2002 and 2013 were reviewed and factors relevant to prognosis and survival were analyzed. The median age of study cohort was 29 years (range, 18-59). The most frequent location was axial (36.2%), followed by involvement of extraskeletal tissues (34.5%) and bones of the extremities (29.3%). Twenty-eight (48.3%) patients had metastatic disease. In cases with localized ES, the 5-year overall survival (OS) was 76.5%. Using the log-rank test, the presence of metastasis at diagnosis, local treatment without surgery and a failure to achieve complete remission were associated with significantly shorter survival. In a multivariate Cox proportional hazard analysis, the achievement of complete remission was an independent predictor of patients's survival time. Outcomes of adults with localized ES treated according to multimodal pediatric protocols are similar to children. The achievement of complete remission is an independent predictor of survival time in ES patients. Severe hematological toxicity is foreseeable and manageable. Prognosis of patients with metastases or progression remains dismal.

Citovat

ADÁMKOVÁ KRÁKOROVÁ, Dagmar, Katerina KUBACKOVA, Ladislav DUŠEK, Tomáš TOMÁŠ, Pavel JANÍČEK, Štěpán TUČEK, Jana PRAUSOVA, Igor KISS a Iva ZAMBO. Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management. PATHOLOGY & ONCOLOGY RESEARCH. DORDRECHT: SPRINGER, 2018, roč. 24, č. 3, s. 623-630. ISSN 1219-4956. Dostupné z: https://dx.doi.org/10.1007/s12253-017-0291-6.

@article{1445757,
   author = {Adámková Krákorová, Dagmar and Kubackova, Katerina and Dušek, Ladislav and Tomáš, Tomáš and Janíček, Pavel and Tuček, Štěpán and Prausova, Jana and Kiss, Igor and Zambo, Iva},
   article_location = {DORDRECHT},
   article_number = {3},
   doi = {http://dx.doi.org/10.1007/s12253-017-0291-6},
   keywords = {Ewing sarcoma; Adults; Multimodal treatment; Risk factors; Prognosis},
   language = {eng},
   issn = {1219-4956},
   journal = {PATHOLOGY & ONCOLOGY RESEARCH},
   title = {Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management},
   volume = {24},
   year = {2018}
}

TY  - JOUR
ID  - 1445757
AU  - Adámková Krákorová, Dagmar - Kubackova, Katerina - Dušek, Ladislav - Tomáš, Tomáš - Janíček, Pavel - Tuček, Štěpán - Prausova, Jana - Kiss, Igor - Zambo, Iva
PY  - 2018
TI  - Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management
JF  - PATHOLOGY & ONCOLOGY RESEARCH
VL  - 24
IS  - 3
SP  - 623-630
EP  - 623-630
PB  - SPRINGER
SN  - 12194956
KW  - Ewing sarcoma
KW  - Adults
KW  - Multimodal treatment
KW  - Risk factors
KW  - Prognosis
N2  - Ewing sarcoma (ES) is an exceptionally rare tumor in adults. Data regarding outcomes of adult patients with ES and experiences with age-adapted therapeutic strategies are very limited. The aim of this study was to evaluate prognostic factors and clinical outcome in a cohort of adult patients treated according to pediatric protocols in the Czech Republic. The records of 58 adult ES patients diagnosed between 2002 and 2013 were reviewed and factors relevant to prognosis and survival were analyzed. The median age of study cohort was 29 years (range, 18-59). The most frequent location was axial (36.2%), followed by involvement of extraskeletal tissues (34.5%) and bones of the extremities (29.3%). Twenty-eight (48.3%) patients had metastatic disease. In cases with localized ES, the 5-year overall survival (OS) was 76.5%. Using the log-rank test, the presence of metastasis at diagnosis, local treatment without surgery and a failure to achieve complete remission were associated with significantly shorter survival. In a multivariate Cox proportional hazard analysis, the achievement of complete remission was an independent predictor of patients's survival time. Outcomes of adults with localized ES treated according to multimodal pediatric protocols are similar to children. The achievement of complete remission is an independent predictor of survival time in ES patients. Severe hematological toxicity is foreseeable and manageable. Prognosis of patients with metastases or progression remains dismal.
ER  -

ADÁMKOVÁ KRÁKOROVÁ, Dagmar, Katerina KUBACKOVA, Ladislav DUŠEK, Tomáš TOMÁŠ, Pavel JANÍČEK, Štěpán TUČEK, Jana PRAUSOVA, Igor KISS a Iva ZAMBO. Advantages in Prognosis of Adult Patients with Ewing Sarcoma: 11-years Experiences and Current Treatment Management. \textit{PATHOLOGY \&{}amp; ONCOLOGY RESEARCH}. DORDRECHT: SPRINGER, 2018, roč.~24, č.~3, s.~623-630. ISSN~1219-4956. Dostupné z: https://dx.doi.org/10.1007/s12253-017-0291-6.

Podrobný výpis o publikaci